Maisie on for Roana Riese's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Roana Riese at Leerink Partners asked for a discussion of the key differentiating factors between Cytokinetics' myosin inhibitors and how they interact with sarcomere function.
Answer
Fady Malik, EVP of R&D, explained that the company's molecules bind to three distinct sites on the myosin motor protein. Aficamtan, omecamtiv mecarbil, and ulicamten each have a unique binding site, leading to different effects on motor function and potentially different clinical profiles, which the company continues to investigate.